Thus, interventions stimulating SIRT1 activity could potentially offer therapeutic benefits for the management of hepatic diseases and metabolic syndrome associated with obesity [93]. This evidence concerns the gene SIRT1 and obesity due to melanocortin 4 receptor deficiency.